Use of semaglutide linked to doubled risk of neovascular macular degeneration

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older patients with diabetes, according to researchers at the University of Toronto.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup